Medication Guide App

Fondaparinux Sodium

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

B01AX05

CAS registry number (Chemical Abstracts Service)

0114870-03-0

Chemical Formula

C31-H43-N3-Na10-O49-S8

Molecular Weight

1728

Therapeutic Category

Anticoagulant agent: Direct, selective inhibitor of blood-coagulation factor Xa

Chemical Name

Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-O-β-D-glucopyranuronosyl-(1->4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-α-D-glucopyranosyl-(1->4)-OR-2-O-sulfo-α-L-idopyranuronosyl-(1->4)-2-deoxy-6-O-sulfo-2-(sulfoamino)-α-D-glucopyrano (WHO)

Foreign Names

  • Fondaparinuxum natricum (Latin)
  • Fondaparinux natrium (German)
  • Fondaparinux sodique (French)
  • Fondaparinux sodico (Spanish)

Generic Names

  • Fondaparinux Sodium (OS: BAN, USAN)
  • Fondaparin sodium (IS)
  • Fondaparinux (IS)
  • IC 851589 (IS)
  • Org 35140 (IS: Organon)
  • Pentasaccharid Faktor Xa-Inhibitor (IS: selektiv)
  • SR 90107A (IS: SanofiSynthela)
  • Xantidar (IS)

Brand Names

  • Arixtra
    Glaxo, Latvia; Glaxo Group, Austria; Glaxo Group, Luxembourg; Glaxo Group, Poland; Glaxo Group, Slovenia; GlaxoSmithKline, Antigua & Barbuda; GlaxoSmithKline, Argentina; GlaxoSmithKline, Australia; GlaxoSmithKline, Aruba; GlaxoSmithKline, Barbados; GlaxoSmithKline, Belgium; GlaxoSmithKline, Bermuda; GlaxoSmithKline, Bahamas; GlaxoSmithKline, Canada; GlaxoSmithKline, Switzerland; GlaxoSmithKline, Chile; GlaxoSmithKline, China; GlaxoSmithKline, Colombia; GlaxoSmithKline, Czech Republic; GlaxoSmithKline, Germany; GlaxoSmithKline, Denmark; GlaxoSmithKline, Ecuador; GlaxoSmithKline, Spain; GlaxoSmithKline, Finland; GlaxoSmithKline, France; GlaxoSmithKline, United Kingdom; GlaxoSmithKline, Grenada; GlaxoSmithKline, Georgia; GlaxoSmithKline, Greece; GlaxoSmithKline, Guyana; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Hungary; GlaxoSmithKline, Indonesia; GlaxoSmithKline, Israel; GlaxoSmithKline, Iceland; GlaxoSmithKline, Italy; GlaxoSmithKline, Jamaica; GlaxoSmithKline, Japan; GlaxoSmithKline, Cayman Islands; GlaxoSmithKline, Saint Lucia; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Netherlands; GlaxoSmithKline, Peru; GlaxoSmithKline, Philippines; GlaxoSmithKline, Portugal; GlaxoSmithKline, Romania; GlaxoSmithKline, Serbia; GlaxoSmithKline, Russian Federation; GlaxoSmithKline, Sweden; GlaxoSmithKline, Singapore; GlaxoSmithKline, Slovakia; GlaxoSmithKline, Thailand; GlaxoSmithKline, Turkey; GlaxoSmithKline, Trinidad & Tobago; GlaxoSmithKline, United States; GlaxoSmithKline, South Africa; Sanofi-aventis, Oman; Wellcome, Bosnia & Herzegowina
  • Fondaparinux Sodium Dr. Reddy's
    Dr. Reddy's, United States
  • Quixidar
    GlaxoSmithKline, Slovakia; Organon, Latvia

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide
(web2)